ALK and neuroblastoma: Only few mechanisms of ALK inhibitor resistance have been detected in preclinical models of neuroblastoma so far, most of which were adaptive epigenetic or gene expression changes that have not yet been observed in patients developing resistance and may not be therapeutically actionable [34–36].